Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

• Authors: Ryan K Shields, Brian A Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G Press, Barry N Kreiswirth, Cornelius J Clancy, M Hong Nguyen
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 63 Issue 12 Pg. 1615-1618 (Dec 15 2016) ISSN: 1537-6591 [Electronic] United States
• PMID: 27624958 (Publication Type: Journal Article)
• Copyright: © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail [email protected].

Chemical References

• Azabicyclo Compounds
• Drug Combinations
• avibactam, ceftazidime drug combination
• beta-Lactamase Inhibitors
• Ceftazidime

Topics

• Adult
• Aged
• Azabicyclo Compounds (adverse effects, therapeutic use)
• Carbapenem-Resistant Enterobacteriaceae
• Ceftazidime (adverse effects, therapeutic use)
• Drug Combinations
• Drug Resistance, Bacterial
• Enterobacteriaceae Infections (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Retrospective Studies
• Treatment Outcome
• beta-Lactamase Inhibitors (adverse effects, therapeutic use)